Patient with metastatic renal cell carcinoma treated successfully with pazopanib for four years.
Journal Title: OncoReview - Year 2015, Vol 5, Issue 3
Abstract
We present a case of a patient with metastatic renal cell carcinoma who was treated with pazopanib in the first-line treatment. Although nephrectomy was not performed, there was a positive reaction to the therapy with multi targeted tyrosine kinase inhibitor. After 18 months of the palliative treatment, the cancerous kidney was surgically removed and pazopanib was restarted with the effect of further disease remission. The development of hypertension, complete hair discoloration and isolated hyperbilirubinemia occurred, and there was occasionally hypokalaemia in laboratory findings within 48 months of therapy. No serious adverse events were reported.
Authors and Affiliations
Agnieszka Słowik, Joanna Streb, Robert Chrzan, Krzysztof Krzemieniecki
Keywords
Related Articles
- EP ID EP78720
- DOI 10.5604/20828691.1171780
- Views 216
- Downloads 0
Aromataze inhibitors in the treatment of breast cancer
The main goal for hormonal therapy of breast cancer is to inhibit action of endogenous estrogens to breast cancer cells. Discovery of hormonal receptors and knowledge of their biological role employment to manner hormona...
Myeloma and amyloid
Rola i miejsce jakości życia w nowoczesnym leczeniu chorych na raka płuca
Jakość życia to osobisty sposób postrzegania przez jednostkę pozycji zajmowanej w życiu w kontekście kultury i systemu wartości oraz w odniesieniu do stawianych sobie celów, oczekiwań i obaw. Chorzy zmieniają postrzegani...
Advanced or metastatic non-small-cell lung cancer treatment - new Polish goverment regulation
The article presents the non-small-cell lung cancer current treatment recommendations in consideration of Polish government regulation.
Jak planuję hormonoterapię u chorego z rakiem gruczołu krokowego – spojrzenie eksperta
Rak gruczołu krokowego w ciągu ostatnich kilkudziesięciu lat stał się jednym z najczęstszych nowotworów u mężczyzn oraz jedną z głównych przyczyn zgonów na nowotwory. Ponieważ jest nowotworem hormonozależnym, od lat 40....